Dyadic International (DYAI) Q1 2025 earnings summary

Executive summary

• Strategic pivot in Q1 2025 toward commercializing high-value, non-pharmaceutical recombinant proteins and enzymes, leveraging proprietary C1 and Dapibus platforms for scalable production in life science, nutrition, and industrial markets.

• Expanded product portfolio with six new products in development, focusing on cell culture media, nucleic acids, and industrial enzymes, and advancing commercialization of non-animal cell culture media, dairy enzymes, reagent proteins, and bioindustrial products.

• Secured major grants from the Gates Foundation ($3.1 million) and CEPI (up to $4.5 million), supporting vaccine and antibody development using the C1 platform.

• Participated in the European Vaccines Hub for Pandemic Readiness, highlighting C1 technology's role in vaccine innovation.

• Commercial launches and milestone payments are imminent, with a robust pipeline and strong collaborations supporting growth and validation across multiple sectors.

Financial highlights

• Total revenue for Q1 2025 increased to $394,000 from $335,000 year-over-year, driven by $210,000 in new grant revenue from the Gates Foundation and CEPI.

• Net loss for Q1 2025 was $2,028,000 ($0.07 per share), compared to $2,100,000 ($0.07 per share) in Q1 2024.

• Cash, cash equivalents, and investment-grade securities totaled $7.3 million as of March 31, 2025, down from $9.3 million at year-end 2024.

• General and administrative expenses decreased by 10.8% year-over-year to $1,596,000.

• Operating loss for Q1 2025 was $2,002,000, down from $2,126,000 in Q1 2024.

Outlook and guidance

• Commercial launch of recombinant human serum albumin with Proliant expected in Q3 2025, with sampling and milestone payment in Q2.

• Additional launches anticipated in animal-free dairy enzymes, transferrin, FGF, alpha-lactalbumin, and human lactoferrin by year-end 2025.

• Revenue sharing from Fermacs/Fermbox Bio is immediate as sales commence, with further growth expected from additional contracts.

• Management expects existing cash, equivalents, and investments to be sufficient for at least the next 12 months, but may seek additional capital for further development and commercialization.

• Focus remains on accelerating product commercialization and maximizing value from partnerships and non-dilutive funding.